Diquafosol Tetrasodium: A Comprehensive Guide to its Pharmaceutical Applications and Benefits
Discover the therapeutic potential of Diquafosol Tetrasodium in treating dry eye and improving ocular surface health.
Get a Quote & SampleProduct Core Value
Diquafosol Tetrasodium
Diquafosol Tetrasodium is a vital pharmaceutical ingredient, recognized for its efficacy in treating dry eye disease. As a potent P2Y2 receptor agonist, it plays a crucial role in stimulating the secretion of mucins and tear fluid from conjunctival epithelial and goblet cells. This action elevates intracellular calcium ion concentrations, directly contributing to enhanced ocular surface lubrication and protection. Its ability to stimulate mucin secretion is key to improving tear film stability, a critical factor in managing dry eye symptoms and preventing further corneal epithelial damage. Rigorous studies, both in vitro and in vivo, have demonstrated its effectiveness in promoting tear fluid secretion and improving the health of the corneal epithelium, making it a valuable component in ophthalmic formulations. The compound is supplied as a pharmaceutical powder, often used in ophthalmic solutions, offering a targeted approach to ocular surface health.
- Explore how Diquafosol Tetrasodium is used to stimulate mucin secretion drug for enhanced eye comfort and protection.
- Learn about the mechanisms behind Diquafosol Tetrasodium's role in improving tear film stability, crucial for managing dry eye conditions.
- Understand the in vivo and in vitro results supporting Diquafosol Tetrasodium's efficacy in treating dry eye disease.
- Find out where to buy Diquafosol Tetrasodium powder and its applications in pharmaceutical formulations.
Product Advantages
Enhanced Ocular Lubrication
By acting as a P2Y2 receptor agonist, Diquafosol Tetrasodium significantly boosts mucin and tear fluid secretion, providing superior lubrication for the ocular surface.
Improved Tear Film Stability
The stimulation of mucin secretion directly leads to a more stable tear film, reducing evaporation and alleviating symptoms associated with dry eye disease.
Corneal Epithelial Protection
Studies show that Diquafosol Tetrasodium effectively improves corneal epithelial damage, safeguarding the delicate surface of the eye.
Key Applications
Dry Eye Disease Treatment
Diquafosol Tetrasodium is a primary therapeutic agent for dry eye, directly addressing the underlying issues of tear deficiency and mucin abnormality.
Ophthalmic Formulations
Its powdered form makes it an ideal active pharmaceutical ingredient for creating sterile ophthalmic solutions designed for topical application.
Ocular Surface Health Management
Beyond dry eye, its properties contribute to overall ocular surface health by promoting natural protective mechanisms.
Research and Development
It serves as a crucial compound for ongoing research into P2Y2 receptor signaling and new therapeutic strategies for ocular conditions.